Toth Financial Advisory Corp Boosts Stake in Ascendis Pharma A/S $ASND

Toth Financial Advisory Corp grew its stake in Ascendis Pharma A/S (NASDAQ:ASND) by 679.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,640 shares of the biotechnology company’s stock after acquiring an additional 4,045 shares during the quarter. Toth Financial Advisory Corp’s holdings in Ascendis Pharma A/S were worth $989,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. Advisory Services Network LLC acquired a new position in Ascendis Pharma A/S in the 3rd quarter valued at about $26,000. Jones Financial Companies Lllp boosted its stake in shares of Ascendis Pharma A/S by 57.2% during the 3rd quarter. Jones Financial Companies Lllp now owns 228 shares of the biotechnology company’s stock worth $44,000 after purchasing an additional 83 shares during the last quarter. Quadrant Capital Group LLC acquired a new stake in shares of Ascendis Pharma A/S during the 3rd quarter worth about $74,000. Farther Finance Advisors LLC grew its holdings in shares of Ascendis Pharma A/S by 115.3% during the third quarter. Farther Finance Advisors LLC now owns 478 shares of the biotechnology company’s stock worth $95,000 after buying an additional 256 shares in the last quarter. Finally, GAMMA Investing LLC grew its holdings in shares of Ascendis Pharma A/S by 15.2% during the third quarter. GAMMA Investing LLC now owns 735 shares of the biotechnology company’s stock worth $146,000 after buying an additional 97 shares in the last quarter.

Ascendis Pharma A/S Price Performance

NASDAQ:ASND opened at $229.25 on Friday. The business’s 50-day moving average is $227.16 and its two-hundred day moving average is $213.91. Ascendis Pharma A/S has a 12 month low of $124.06 and a 12 month high of $248.60. The firm has a market capitalization of $14.29 billion, a PE ratio of -52.10 and a beta of 0.49.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its earnings results on Thursday, February 12th. The biotechnology company reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.58). The company had revenue of $290.38 million during the quarter, compared to analyst estimates of $285.35 million. Equities analysts anticipate that Ascendis Pharma A/S will post -4.34 EPS for the current year.

Wall Street Analysts Forecast Growth

ASND has been the topic of several recent analyst reports. Morgan Stanley reissued an “overweight” rating and set a $256.00 price objective on shares of Ascendis Pharma A/S in a research note on Thursday, February 12th. TD Cowen reiterated a “buy” rating on shares of Ascendis Pharma A/S in a report on Wednesday, January 7th. Wells Fargo & Company increased their price target on Ascendis Pharma A/S from $322.00 to $330.00 and gave the stock an “overweight” rating in a research note on Tuesday, January 20th. Oppenheimer raised their price objective on Ascendis Pharma A/S from $246.00 to $262.00 and gave the stock an “outperform” rating in a report on Thursday, February 12th. Finally, The Goldman Sachs Group reaffirmed a “buy” rating and issued a $255.00 price objective on shares of Ascendis Pharma A/S in a research report on Monday, March 2nd. One investment analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $289.89.

About Ascendis Pharma A/S

Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.